Latest 8-K filings

Holley Inc. announced second quarter 2026 results, showcasing a 3.2% net sales increase to $172.0 million and double-digit core growth in three of four divisions, alongside a leverage ratio at a four-year low.

Immuneering Corporation announced its second quarter 2026 financial results, highlighting progress in its Phase 3 MAPKeeper 301 trial for pancreatic cancer and a cash runway extending into 2029.

EVgo Inc. announced second quarter 2026 results, showcasing a 19% year-over-year increase in charging network revenue to $61 million and an expansion to 5,380 stalls, alongside a significant partnership with Tesla.

Bioventus Inc. announced second quarter 2026 financial results showing a 4% revenue increase and reaffirmed full-year guidance, while simultaneously initiating a review of strategic alternatives following unsolicited acquisition interest.

Medline Inc. announced second quarter and first six months 2026 results, showing an 11.6% increase in net sales to $7.7 billion but a 58.3% decrease in net income to $139 million.

Royalty Pharma plc reported robust second quarter 2026 financial results, with significant growth in Royalty Receipts and an increase in Portfolio Receipts, leading to an upward revision of full-year 2026 guidance.

Summit Therapeutics announces the initiation of a global Phase II/III HARMONi-GU1 trial for ivonescimab in first-line bladder cancer, expanding its development program.

Vishay Intertechnology announced robust second quarter 2026 financial results, exceeding revenue guidance with significant sequential growth and improved margins.

ContextLogic Holdings Inc. announced a definitive agreement to acquire specialty chemicals company gChem for $850 million, marking its second operating business acquisition and aiming for significant free cash flow accretion.

Kyndryl announced its first fiscal quarter 2027 results, reporting a net loss of $55 million on revenues of $3.6 billion, a 3% decrease year-over-year.

Prologis, Inc. has successfully completed an underwritten public offering of 15,000,000 shares of its common stock, raising approximately $2.1 billion in net proceeds.

CDW Corporation announced that Chief Financial Officer Albert J. Miralles intends to retire in 2027, with a transition plan in place to ensure continuity.

CS Disco announced second quarter 2026 financial results, reporting a 13% year-over-year increase in total revenue to $43.1 million, alongside the launch of a new unified litigation solution.

Lifecore Biomedical reported a decrease in revenue and gross profit for Q2 2026 compared to the prior year, while reaffirming its full-year financial guidance and highlighting new business wins.

Rapport Therapeutics announced second quarter 2026 financial results, highlighting the initiation of its Phase 3 RAP-219 program for focal onset seizures and continued pipeline advancement.

Charles River Laboratories reported Q2 2026 results, exceeding prior outlook and increasing full-year guidance for revenue and non-GAAP EPS due to improving demand in DSA and Manufacturing segments.

Dine Brands Global reported Q2 2026 results with total revenues rising to $240.9 million, but net income and adjusted EBITDA declined year-over-year due to increased expenses.

Natural Resource Partners L.P. reported second quarter 2026 results, generating $41.7 million in free cash flow and declaring a $0.75 per common unit distribution.

Verano Holdings Corp. announced robust second quarter 2026 financial results, featuring $218 million in revenue and improved operational cash flow, marking the third consecutive quarter of revenue gains.

Advantage Solutions announced its second quarter 2026 financial results, reporting revenue growth but a substantial net loss and a decrease in Adjusted EBITDA, while reiterating full-year guidance.

Extreme Networks announced robust fourth quarter and fiscal year 2026 financial results, highlighted by 13% year-over-year revenue growth and significant increases in SaaS ARR.

Ivanhoe Electric Inc. announced the appointment of Michelle Lammers as Chief Operating Officer, effective September 1, 2026, to enhance its operational leadership.

Kymera Therapeutics reported strong Q2 2026 results, highlighted by accelerated trial enrollment for KT-621, significant milestone payments from partnerships, and a cash runway extending into 2029.

NewAmsterdam Pharma announced a positive CHMP opinion recommending marketing authorization for its cardiovascular treatments, obicetrapib and obicetrapib/ezetimibe, alongside its second-quarter financial results.

LCI Industries announced second quarter 2026 results, showing a 16% increase in net income to $67 million and expanded operating profit margins, driven by cost efficiencies and a proposed merger with Patrick Industries.

SilverBox Corp IV has amended its business combination agreement to extend the outside date to December 31, 2026, allowing more time for the merger with Parataxis Holdings Inc.

Spire Inc. announced its fiscal 2026 third quarter results, reporting a net loss from continuing operations but reaffirming full-year adjusted earnings guidance.

Regal Rexnord announced robust second-quarter 2026 financial results, showcasing significant year-over-year growth in sales, net income, and adjusted EBITDA.

CDW Corporation announced robust second quarter 2026 financial results, showcasing a 10.0% increase in net sales and a 5.1% rise in diluted earnings per share, alongside the declaration of a quarterly cash dividend.

Gran Tierra Energy Inc. has agreed to sell its Colombia and Ecuador oil business to Maurel & Prom for $1.33 billion, aiming to become debt-free and fund future growth.